Literature DB >> 11150343

Enhanced cortical extracellular levels of cholecystokinin-like material in a model of anticipation of social defeat in the rat.

C Becker1, M H Thièbot, Y Touitou, M Hamon, F Cesselin, J J Benoliel.   

Abstract

The involvement of cholecystokinin (CCK) in the mechanisms of stress and/or anxiety was assessed by in vivo microdialysis in rats subjected to a social stress paradigm. During the initial 30 min period of each conditioning session, a male Sprague Dawley rat (intruder) was placed in a protective cage inside the cage of a male Tryon Maze Dull rat (resident), allowing unrestricted visual, olfactory, and auditory contacts but precluding close physical contact between them. During the following 15 min period, both the protective cage and the resident were removed (nondefeated intruders) or only the protective cage was removed allowing the resident to attack the intruder (defeated rats). This procedure was repeated once daily for 4 d. On the fifth day, a guide cannula was implanted into the prefrontal cortex of intruders. During a single 30 min test session, performed 4 d later, intruders were subjected to only the 30 min protected confrontation to the resident. Anxiety-like behavior (immobility, ultrasonic vocalizations, and defensive postures), associated with an increase (approximately +100% above baseline) in cortical outflow of CCK-like material (CCKLM), were observed in defeated intruders. Pretreatment with diazepam (5 mg/kg, i.p.), but not buspirone (0.5-2 mg/kg, i.p.), prevented both the anxiety-related behavior and CCKLM overflow. The selective CCK-B receptor antagonist CI-988 (2 mg/kg, i.p.) reduced the anxiety-like behavior without affecting the increase in CCKLM outflow. These data indicate that anticipation of social defeat induces a marked activation of cortical CCKergic neurons associated with anxiety-related behaviors in rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150343      PMCID: PMC6762450     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

Authors:  C de Montigny
Journal:  Arch Gen Psychiatry       Date:  1989-06

2.  The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.

Authors:  L Singh; M J Field; J Hughes; R Menzies; R J Oles; C A Vass; G N Woodruff
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

3.  Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs.

Authors:  J De Vry; U Benz; R Schreiber; J Traber
Journal:  Eur J Pharmacol       Date:  1993-11-16       Impact factor: 4.432

4.  Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics.

Authors:  J Harro; R A Kiivet; A Lang; E Vasar
Journal:  Behav Brain Res       Date:  1990-06-18       Impact factor: 3.332

5.  Diazepam and gepirone selectively attenuate either 20-32 or 32-64 kHz ultrasonic vocalizations during aggressive encounters.

Authors:  J A Vivian; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.

Authors:  G Griebel
Journal:  Pharmacol Ther       Date:  1995-03       Impact factor: 12.310

7.  GABA, acting at both GABAA and GABAB receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro.

Authors:  J J Benoliel; S Bourgoin; A Mauborgne; M Pohl; J C Legrand; M Hamon; F Cesselin
Journal:  Brain Res       Date:  1992-09-11       Impact factor: 3.252

8.  Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein.

Authors:  E Vasar; E Peuranen; J Harro; A Lang; L Oreland; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

9.  Behavioral and autonomic responses to intermittent social stress: differential protection by clonidine and metoprolol.

Authors:  W Tornatzky; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

10.  Stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: prevention by diazepam but not ondansetron.

Authors:  I Nevo; C Becker; M Hamon; J J Benoliel
Journal:  J Neurochem       Date:  1996-05       Impact factor: 5.372

View more
  16 in total

1.  DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.

Authors:  Vincent Vialou; Alfred J Robison; Quincey C Laplant; Herbert E Covington; David M Dietz; Yoshinori N Ohnishi; Ezekiell Mouzon; Augustus J Rush; Emily L Watts; Deanna L Wallace; Sergio D Iñiguez; Yoko H Ohnishi; Michel A Steiner; Brandon L Warren; Vaishnav Krishnan; Carlos A Bolaños; Rachael L Neve; Subroto Ghose; Olivier Berton; Carol A Tamminga; Eric J Nestler
Journal:  Nat Neurosci       Date:  2010-05-16       Impact factor: 24.884

2.  Pituitary adenylate cyclase-activating polypeptide (PACAP) in the bed nucleus of the stria terminalis (BNST) increases corticosterone in male and female rats.

Authors:  K R Lezak; E Roelke; O M Harris; I Choi; S Edwards; N Gick; G Cocchiaro; G Missig; C W Roman; K M Braas; D J Toufexis; V May; S E Hammack
Journal:  Psychoneuroendocrinology       Date:  2014-03-25       Impact factor: 4.905

3.  Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies.

Authors:  Judith Andre; Brigitte Zeau; Michel Pohl; François Cesselin; Jean-Jacques Benoliel; Chrystel Becker
Journal:  J Neurosci       Date:  2005-08-31       Impact factor: 6.167

4.  Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test.

Authors:  Sirli Raud; Jürgen Innos; Urho Abramov; Ain Reimets; Sulev Kõks; Andres Soosaar; Toshimitsu Matsui; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  Involvement of the dorsomedial hypothalamus and the nucleus tractus solitarii in chronic cardiovascular changes associated with anxiety in rats.

Authors:  Caroline Sévoz-Couche; Charly Brouillard; Françoise Camus; Dominique Laude; Sietse F De Boer; Chrystel Becker; Jean-Jacques Benoliel
Journal:  J Physiol       Date:  2013-01-07       Impact factor: 5.182

6.  Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression.

Authors:  E Bouvier; F Brouillard; J Molet; D Claverie; J-H Cabungcal; N Cresto; N Doligez; C Rivat; K Q Do; C Bernard; J-J Benoliel; C Becker
Journal:  Mol Psychiatry       Date:  2016-09-20       Impact factor: 15.992

7.  Maternal deprivation increases behavioural reactivity to stressful situations in adulthood: suppression by the CCK2 antagonist L365,260.

Authors:  Vincent Vazquez; Séverine Farley; Bruno Giros; Valérie Daugé
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 8.  Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake.

Authors:  Klaus A Miczek; Jasmine J Yap; Herbert E Covington
Journal:  Pharmacol Ther       Date:  2008-08-15       Impact factor: 12.310

9.  Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB.

Authors:  Vincent Vialou; Rosemary C Bagot; Michael E Cahill; Deveroux Ferguson; Alfred J Robison; David M Dietz; Barbara Fallon; Michelle Mazei-Robison; Stacy M Ku; Eileen Harrigan; Catherine A Winstanley; Tej Joshi; Jian Feng; Olivier Berton; Eric J Nestler
Journal:  J Neurosci       Date:  2014-03-12       Impact factor: 6.167

10.  Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat.

Authors:  Santiago J Ballaz; Michel Bourin; Huda Akil; Stanley J Watson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-09-14       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.